A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cutaneous Warts
- Conditions
- Cutaneous warts10014982
- Registration Number
- NL-OMON41194
- Lead Sponsor
- Centre for Human Drug Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
1.Healthy subjects (male, non-pregnant female), 18 to 65 years of age, inclusive. (Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs,12-lead ECG, haematology, blood chemistry, and urinalysis.);;2.Body mass index (BMI) between 18 and 30 kg/m2, inclusive;;3.Fitzpatrick skin type I-II-III-IV;;4.Capable of tolerating treatment;;5.Free of clinical significant systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of Adverse Events;6. Have at least 2 (non-subungual) common warts or at least 2 (non-subungual) plantar warts on non-genital, non-facial skin of which at least 2 are 3mm in diameter in their longest dimensions on the plane of the skin ;7.If female of childbearing potential, have a negative urine pregnancy test at Screening/Day 1, and is willing to use effective contraception during the study (i.e. oral, implanted, injectable, IUD, diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy);;8.Able to participate and willing to give written informed consent and to comply with the study restrictions;;9.Ability to communicate well with the investigator in the Dutch language;;10.Free of any clinical significant systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of Adverse Events;;11.Willing to refrain from using cosmetics or other topical products in the treatment area, or prohibited medications for the duration of the study;;12.Agree not to use any wart-removing product (prescription or over-the-counter) other than the study product during the course of the study
Eligible subjects must meet none of the following exclusion criteria:;1.Any clinically significant abnormality as determined by medical history taking and physical examinations obtained during the screening visit that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;;2.For women: a positive pregnancy test and/or nursing at screening or women who plan to become pregnant or are breastfeeding.;3.A positive test for drugs of abuse at screening;;4.History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption > 28 units/week);;5.Positive test results for Hepatitis B, Hepatitis C or HIV;;6.Have used salicylic acid or any other over-the-counter wart-removing product in the treatment area within 30 days prior to enrolment;;7.Have received cryotherapy in the treatment area within 60 days prior to enrolment;;8.Have required systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 30 days prior to enrolment or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed; ;9.Have any current and / or recurrent pathologically relevant skin infections in the treatment area other than common warts (with the exception of herpes simplex virus labialis);;10.Have a known sensitivity to any of the investigational product ingredients, including digoxin and furosemide;;11.Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings at screening that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;;12.Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year;;13.Any psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol;;14.Not having a general practitioner;;15.Not willing to accept information transfer which concerns participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner;;16.Not willing to give permission to have the general practitioner to be notified upon participation in this study;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Pharmacodynamic / efficacy endpoints<br /><br>Pharmacodynamic effects of CLS003 will be assessed at the time points indicated<br /><br>in the Visit and<br /><br>Assessment Schedule (Table 1) by<br /><br>• Morphological wart assessment on-site;<br /><br>• Wart size and morphology assessment by standardized clinical photography;<br /><br>• HPV viral load assessment of target lesions by quantitative PCR including HPV<br /><br>genotyping in swabs and biopsies.<br /><br>• Percent reduction in wart area at Week 6 to baseline<br /><br>• Percent reduction in wart area at follow-up Weeks 10 and 14 to baseline<br /><br>• Change in the HPV viral load (nominal, natural log transformed, and natural<br /><br>log of viral load per DNA copies) as determined by qPCR at Weeks 0, 2,4,6, 10<br /><br>and 14 to baseline<br /><br>• Mean HPV viral load (nominal, natural log transformed, and natural log of<br /><br>viral load per DNA copies)at treatment weeks and overall<br /><br>• Percent clearance of warts</p><br>
- Secondary Outcome Measures
Name Time Method <p>Tolerability / safety endpoints<br /><br>Adverse events (AE) will be collected throughout the study, at every study<br /><br>visit. Vital signs will be collected at baseline and weeks 1, 4, 6, 10 and 14.<br /><br>Plasma digoxin levels will be determined by therapeutic drug monitoring (TDM)<br /><br>at week 2, week 4 and week 6. ECGs will be performed at screening and week 14<br /><br>(EOS).</p><br>